MEGGLE introducing new faces at EFIDD Conference, Parma

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will make its debut at the upcoming International Conference & Galenus Workshop in Parma, Italy, that brings together the drug inhalation pharma scientific community.

As a Silver Sponsor of the “Exploring the Future of Inhalation Drug Delivery “(EFIDD) Conference at University of Parma, MEGGLE will be a prominent presence at the September 2024 event.

New additions

The MEGGLE team in Parma will take advantage of the conference to hear scientific insights into the latest advancements in the formulation and development of inhaled medicines. They will also use the event to introduce new team members.

Head of R&D Ms. Ricarda Leister will introduce Tristan Mul as MEGGLE’s new Business Development Manager for the Inhalation sector.

Mr. Mul’s primary responsibility will be the company’s extensive portfolio of InhaLac^® lactose monohydrate-based excipients for Dry Powder Inhalation, recently boosted by the introduction of a new intermediate grade InhaLac^® 145.

About MEGGLE

Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose^®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose^® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About EFIDD 2024

The International Conference “Exploring the Future of Inhalation Drug Delivery “(EFIDD) will focus on the latest advancements in the formulation and development of inhaled medicines.

The conference and associated workshop form a three-day event opening September 11, 2024, and hosted on the campus of the University of Parma, chaired by the university’s Prof. Francesca Buttini.

Thematic sessions will delve into various aspects of IDD, including the inhalation of biologics such as proteins or DNA/RNA-based therapies, novel treatments for unmet diseases (such as cough, cancer, lung infection, and idiopathic pulmonary fibrosis), MDI propellant transition, and nose-to-brain delivery.

The event is organized by the University of Parma and supported by the Galenus Foundation with further details at: https://newaurameeting.it/international-conference-and-galenus-workshop/.

Resources

Click on MEGGLE InhaLac^® for Dry Powder Inhalation  for further information.